0
0
11/15/22 at 7:00pm
Organization
CNBC
Author
Alex Harring
35 words
0
Comments
It may be time for investors to jump into little-known biotech stock Fulcrum Therapeutics, according to Goldman Sachs.
You are the first to view
https://www.cnbc.com/2022/11/15/this-little-known-biotech-stock-can-surge-60percent-on-promising-drug-trials-goldman-sachs-says.html
Create an account
or login to join the discussion